TNF is here to stay--revisited.

[1]  F. Balkwill,et al.  TNF is here to stay! , 2000, Immunology today.

[2]  A. Eggermont,et al.  Low‐dose tumor necrosis factor‐α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma‐bearing rats , 2000, International journal of cancer.

[3]  A. Eggermont,et al.  Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model , 2000, Journal of immunotherapy.

[4]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[5]  A. Eggermont,et al.  TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.

[6]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[7]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[8]  A. Eggermont,et al.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.

[9]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[10]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. K. Jain,et al.  Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. , 1996, British Journal of Cancer.

[12]  S D Prionas,et al.  Dual role of tumor necrosis factor-alpha in angiogenesis. , 1992, The American journal of pathology.

[13]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.